title: Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329.
abstract: Two different classes of 1,3-beta-glucan synthesis inhibitors, the echinocandins and papulacandins, have anti-Pneumocystis activity in an immunosuppressed rat model for acute P. carinii pneumonia (PCP). This activity combined with potent anti-Candida activity makes the echinocandins attractive agents for treating both Pneumocystis and candidiasis in the immunocompromised patient. Natural product echinocandin L-671,329 rapidly eliminates greater than 99% of the P. carinii cysts after 4 days of treatment at a dose of 1 mg/kg twice daily while 2-3 weeks of therapy with trimethoprimsulfamethoxazole (TMP-SMZ) or pentamidine was required to achieve the same degree of cyst clearance. Effects of L-671,329, TMP-SMZ and pentamidine on the trophozoite stage of P. carinii were also explored using a P. carinii-specific DNA probe to quantitate organism load. Although L-671,329 was not as effective as the known agents against the trophozoite stage, prophylactic use of L-671,329 at a daily dose of 1 mg/kg prevented the development of cysts and trophozoites in the rat model. The foamy exudate commonly seen in lungs of animals with PCP is also absent in rats receiving L-671,329 prophylaxis. In addition to demonstrating the potential of L-671,329 as a prophylactic agent these studies also help in elucidating the life cycle of P. carinii. The observation that L-671,329 prophylaxis prevents the appearance of trophozoites, while acute therapy does not directly affect trophozoites, provides the first evidence that the cyst stage is required for trophozoite proliferation. The rapid elimination of cysts by L-671,329 in animals with acute PCP also indicates that all cysts are turning over within 4 days since it is the development of new cysts which is prevented with this compound.
authors.affiliation: Department of Biochemical Parasitology, Merck Sharp & Dohme Research Laboratories, Rahway, N.J. 07065.
authors.forename: D M
authors.initials: DM
authors.lastname: Schmatz
authors.forename: M
authors.initials: M
authors.lastname: Powles
authors.forename: D C
authors.initials: DC
authors.lastname: McFadden
authors.forename: L A
authors.initials: LA
authors.lastname: Pittarelli
authors.forename: P A
authors.initials: PA
authors.lastname: Liberator
authors.forename: J W
authors.initials: JW
authors.lastname: Anderson
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents; D000935:Antifungal Agents / Q000737:chemistry / Q000627:therapeutic use*; D004195:Disease Models, Animal; D054714:Echinocandins; D005936:Glucans / Q000096:biosynthesis*; D015394:Molecular Structure; D010455:Peptides; D010456:Peptides, Cyclic / Q000737:chemistry / Q000627:therapeutic use; D011010:Pneumocystis / Q000187:drug effects / Q000254:growth & development*; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy* / Q000517:prevention & control; D051381:Rats; D047071:beta-Glucans
chemical_list: D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D054714:Echinocandins; D005936:Glucans; D010455:Peptides; D010456:Peptides, Cyclic; D047071:beta-Glucans; C058995:pneumocandin A(0); C033363:beta-1,3-glucan